Boston Scientific Hit by Global Cyberattack Causing Operational Disruption
Medical device manufacturer Boston Scientific is experiencing a global operational disruption due to an ongoing cybersecurity incident that began Tuesday, impacting IT systems and business applications.
Medical device maker Boston Scientific has disclosed that its global operations have been significantly disrupted by an ongoing cyberattack. The company revealed in an SEC filing that the cybersecurity incident, which commenced on Tuesday, has led to a "global disruption to the company's operations." Upon detection of unauthorized access to its IT systems, Boston Scientific initiated an investigation with the assistance of third-party cybersecurity experts who are actively working to contain the threat.
The incident has resulted in, and is expected to continue to cause, disruptions and limitations in accessing certain of the company's information systems and business applications. These affected systems are critical for supporting various aspects of the company's operations, including its ability to process and ship customer orders. The full extent and nature of the cyberattack, along with its operational and financial impacts, remain unknown at this time, and Boston Scientific has not provided a timeline for full system restoration.
The news of the cyberattack had an immediate negative effect on the company's stock, with Boston Scientific shares reportedly falling more than 4% on Wednesday morning. As of the disclosure, no known threat actor groups have claimed responsibility for the intrusion.
This incident follows a trend of cyberattacks targeting the healthcare and medical device sectors. In March, Stryker, another major medical technology company, experienced a global network outage attributed to a cyber crew with ties to Iran's intelligence agency. More recently, in April, medical-device maker Medtronic disclosed its own cyberattack, which was claimed by the notorious data-theft-and-extortion group ShinyHunters. Medtronic later warned patients that their personal and health information had been compromised in that breach.
The lack of immediate attribution makes it difficult to pinpoint the exact motives or origin of the attack on Boston Scientific. However, the disruption to order processing and shipping suggests potential impacts on supply chains and customer service, which could have significant financial repercussions for the company.
Boston Scientific's reliance on interconnected IT systems for its complex manufacturing and distribution processes makes it a prime target for cybercriminals seeking to extort money or cause widespread disruption. The company's statement emphasizes the ongoing nature of the investigation and the uncertainty surrounding the full scope of the breach, underscoring the challenges in fully assessing and mitigating such sophisticated attacks.
As the investigation progresses, further details may emerge regarding the specific tactics, techniques, and procedures (TTPs) employed by the attackers, as well as the potential vulnerabilities exploited. The medtech industry, with its critical infrastructure and sensitive data, remains a high-value target for various threat actors, necessitating continuous vigilance and robust cybersecurity defenses.
Boston Scientific has disclosed that the ongoing cybersecurity incident discovered on Tuesday has specifically disrupted its shipment processes. The company also filed documents with the Securities and Exchange Commission (SEC) detailing the discovery of the incident, though further specifics on the attack vector or affected systems remain undisclosed.
The cyberattack on Boston Scientific has disrupted the company's ability to process and ship customer orders, impacting its global operations. While the full scope and financial impact are still under investigation, the company has activated incident response protocols with the assistance of third-party cybersecurity experts. This incident follows a pattern of recent cyberattacks targeting other medical technology firms, including Baxter International, Medtronic, and Abbott Laboratories.
Boston Scientific has confirmed that the cyber incident has led to significant global IT outages, impacting its operations worldwide. While the company has not yet detailed the specific nature of the attack or the exact systems affected, investigations are actively underway to ascertain the full scope and consequences of the disruption.
The cybersecurity incident affecting Boston Scientific, first reported on August 25, has led to a global disruption impacting the company's ability to process and ship customer orders. While the exact attack vector, malware, and threat actor remain undisclosed, the company has filed an SEC report acknowledging the ongoing investigation into the full scope and impacts of the incident. It is currently unclear if sensitive data has been compromised.
The cyberattack on Boston Scientific, which began on August 25, has led to a disruption in the company's ability to process and ship customer orders. While the full extent of the impact is still under investigation, Boston Scientific has stated that it has not yet determined if the incident is reasonably likely to have a material impact on its business. The company is working with third-party cybersecurity experts to assess and contain the threat.
While the initial report focused on the broad operational disruption, this article provides specific details on how the cyberattack is hindering remote monitoring capabilities for certain newer cardiac devices. Boston Scientific clarified that while existing remote monitoring for older CRM devices remains unaffected, new remote monitoring activations for some newer cardiac implants and insertable cardiac monitors are currently not possible due to IT system outages. This prevents the transmission of newly collected patient data until the network is restored and communicators can be reactivated.
Boston Scientific has confirmed that it has engaged cybersecurity firms, including CrowdStrike, to investigate the ongoing cyberattack. The company is still in the process of recovering from the incident, which has caused global network disruptions and impacted IT systems and business applications. The full scope of the attack and the specific methods used by the attackers remain under investigation.
Boston Scientific has provided further details on the ongoing cyberattack impacting its IT systems, confirming that new pacemakers and other heart devices implanted since August 25 cannot be remotely monitored. The company also stated that the intrusion has affected manufacturing, shipping, and ordering processes, with partial restoration of shipping expected this week. While Boston Scientific has hired CrowdStrike for assistance, they have not disclosed whether the incident involves ransomware or identified the responsible threat actor.
The ongoing cyberattack against Boston Scientific, initially detected on August 25, 2026, has led to further operational disruptions beyond manufacturing and order processing. The company has confirmed that new remote monitoring activations for Cardiac Rhythm Management (CRM) devices are affected, delaying the transmission of device data to remote patient management systems. While existing remotely monitored devices and new activations for insertable cardiac monitors remain functional for data recording, the inability to activate new communicators for newly implanted CRM devices and pair insertable cardiac monitors with mobile phones for remote transmission presents a significant challenge for patient care continuity.
Boston Scientific has now disclosed the expected financial impact of the cyberattack, stating it is unlikely to meet its sales growth and adjusted earnings guidance for the third quarter and the full year. The medical device manufacturer anticipates a "material impact" on its financial results due to the disruption, though it expects to recover some revenue by clearing a backlog of orders. While distribution and manufacturing operations have largely resumed, the company has not yet identified the attack vector, the responsible party, or if any data was exfiltrated.